Australia markets closed
  • ALL ORDS

    7,726.80
    -1.70 (-0.02%)
     
  • ASX 200

    7,415.50
    +0.10 (+0.00%)
     
  • AUD/USD

    0.7468
    -0.0003 (-0.04%)
     
  • OIL

    83.98
    +1.48 (+1.79%)
     
  • GOLD

    1,793.10
    +11.20 (+0.63%)
     
  • BTC-AUD

    81,843.70
    -3,867.94 (-4.51%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • AUD/EUR

    0.6407
    -0.0015 (-0.23%)
     
  • AUD/NZD

    1.0428
    -0.0004 (-0.04%)
     
  • NZX 50

    13,093.24
    -32.74 (-0.25%)
     
  • NASDAQ

    15,355.07
    -134.52 (-0.87%)
     
  • FTSE

    7,204.55
    +14.25 (+0.20%)
     
  • Dow Jones

    35,677.02
    +73.94 (+0.21%)
     
  • DAX

    15,542.98
    +70.42 (+0.46%)
     
  • Hang Seng

    26,126.93
    +109.40 (+0.42%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, September 02, 2021--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September:

  • 2021 Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 2:00 p.m. ET

  • Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 2:45 p.m. ET

A live webcast of Ironwood’s fireside chats will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005017/en/

Contacts

Investors:
Matt Roache, 617-621-8395
Director, Investor Relations
mroache@ironwoodpharma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting